Prospective Evaluation of Thrombotic Complications After Internal Jugular Vein Cannulation for External Bypass
Journal of Cardiothoracic and Vascular Anesthesia · 2025
DOI: 10.1053/j.jvca.2025.08.027 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift Journal of Cardiothoracic and Vascular Anesthesia, 2025. Verfasst von Armin Niklas Flinspach und 3 weiteren Autor:innen. Beteiligte Einrichtung: Goethe-University Frankfurt, University Hospital Frankfurt, Department of Anaesthesiology, Intensive Care Medicine and Pain Therapy, Frankfurt, Germa…. Hauptthemen laut MEDLINE: Jugular Veins, Catheterization, Central Venous, Cardiopulmonary Bypass, Postoperative Complications. Die Arbeit nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Goethe-Universitat Frankfurt am Main.
Abstract (Originalsprache)
OBJECTIVES: To determine the incidence and subsequent complications of internal jugular vein (IJV) thrombosis after cannulation performed during cardiopulmonary bypass (CPB) to ensure adequate venous drainage during minimally invasive cardiac surgery. DESIGN: Single-center observational trial SETTINGS: Intensive care postoperative monitoring of cardiac surgery patients and diagnosis of IJV thrombi at a university tertiary hospital during the 13-month study period from December 1, 2022, to January 11, 2024. PARTICIPANTS: 44 patients undergoing catheterization of the IJV for total CPB. INTERVENTION: Structured ultrasound of the IJV at 12 to 16 hours after removing the cannula, in the context of intensive care therapy. MEASUREMENTS & MAIN RESULTS: The incidence of ultrasound-detected IJV thrombi was 79.5%. Thrombi located at the insertion site were smaller compared to those located distally. No major complications were observed during cannula insertion or removal, and none of the patients had clinical symptoms related to IJV thrombi. There were no correlations between cannula size (p = 0.886), intravascular insertion length (p = 0.086), duration of CPB (p = 0.094), or body weight (p = 0.590). CONCLUSIONS: Although IJV thrombosis was frequent, all cases remained clinically silent. These findings suggest that although thrombus formation is common, the risk of symptomatic or obstructive thrombosis may be low. Structured ultrasound follow-up and a risk-adapted anticoagulation strategy, as suggested by recent ESVS guidelines, may optimize postoperative management and outcomes.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Goethe-University Frankfurt, University Hospital Frankfurt, Department of Anaesthesiology, Intensive Care Medicine and Pain Therapy, Frankfurt, Germany. Electronic address: Flinspach@med.uni-frankfurt.de.
- Goethe-University Frankfurt, University Hospital Frankfurt, Department of Anaesthesiology, Intensive Care Medicine and Pain Therapy, Frankfurt, Germany.
- Goethe-University Frankfurt, University Hospital Frankfurt, Department of Anaesthesiology, Intensive Care Medicine and Pain Therapy, Frankfurt, Germany; Department of Anesthesiology and Intensive Care Medicine, Rheinisc…
Förderung
- Goethe-Universitat Frankfurt am Main
Zitieren
APA
Flinspach, A. N., Zacharowski, K., Raimann, F. J., & Piekarski, F. (2025). Prospective Evaluation of Thrombotic Complications After Internal Jugular Vein Cannulation for External Bypass. Journal of Cardiothoracic and Vascular Anesthesia. https://doi.org/10.1053/j.jvca.2025.08.027
Vancouver
Flinspach AN, Zacharowski K, Raimann FJ, Piekarski F. Prospective Evaluation of Thrombotic Complications After Internal Jugular Vein Cannulation for External Bypass. Journal of Cardiothoracic and Vascular Anesthesia. 2025. doi:10.1053/j.jvca.2025.08.027
BibTeX
@article{Flinspach2025,
author = {Flinspach, Armin Niklas and Zacharowski, Kai and Raimann, Florian Jürgen and Piekarski, Florian},
title = {Prospective Evaluation of Thrombotic Complications After Internal Jugular Vein Cannulation for External Bypass},
journal = {Journal of Cardiothoracic and Vascular Anesthesia},
year = {2025},
doi = {10.1053/j.jvca.2025.08.027}
}
EUVIMED